

## United States Patent and Trademark Office



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO	
09/365,241	07/30/1999	THOMAS BRODIN	003300-581	1539	
21839	7590 10/08/2002				
BURNS DOANE SWECKER & MATHIS L L P			EXAMINER		
POST OFFICE BOX 1404 ALEXANDRIA, VA 22313-1404			PONNALURI, I	PONNALURI, PADMASHRI	
			ART UNIT	PAPER NUMBER	
		~	1639	•	
			DATE MAILED: 10/08/2002		

Please find below and/or attached an Office communication concerning this application or proceeding.



## UNITED STATES DEPARTMENT OF COMMERCE Patent ar ademark Offic COMMISS. NER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

EA/FCE-1994

SERIAL NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.
09/365,241	7/30/99	, , , , , , , , , , , , , , , , , , , ,	

EXAMINER

P. Ponnaluri

ART UNIT PAPER NUMBER

1639 27

DATE MAILED:

## Please find below a communication from the EXAMINER in charge of this application

Commissioner of Patents

Application No.: 09/365,241

Art Unit: 1639

## NOTE the change of AU Unit to AU 1639 of this application.

1. The reply filed on 7/18/02, paper number 26, is not fully responsive to the prior Office action because of the following omission(s) or matter(s):applicants have canceled original claims 1-4, 6-7, 9-10, 17-27, 29, 33-57 and 61-64 and added new claims 65-94.

Applicants have elected with traverse the following species:

- a) receptor as target structure; b) pathological process as physiological process;
- c) infammation as pathological process; d) extracellular as location of the target structure; e) bone marrow as tissue type; f) combinatorial library as initial library; g) immunization as methods of production of library; h) amplifying by PCR;
- I) proteolytic as cleavage site; j) blood clotting factor Xa as protease.

However, the newly added claims use an initial library of nonoclonal anitobody or scFv/Fab fragment library, wherein the monoclonal antibody of scFv/Fab antibody would be specific to an antigen. Applicants are requested to elect a single monoclaonl antibody. And further the new claims use antibody identifying sequence information, applicants are requested to elect a single species of sequence identifying information. Applicants response does not include species election of the above, thus the response is not proper. See 37 CFR 1.111. Since the above-

mentioned reply appears to be bona fide, applicant is given ONE (1) MONTH or THIRTY

(30) DAYS from the mailing date of this notice, whichever longer, within which to supply the omission or correction in order to avoid abandonment. EXTENSIONS OF THIS TIME PERIOD MAY BE GRANTED UNDER 37 CFR 1.136(a).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to P. Ponnaluri whose telephone number is (703) 305-3884. The examiner is on *Increased*Flex Schedule and can normally be reached on Monday to Friday from 7.00 AM to 3.30 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Andrew Wang, can be reached on (703) 306-3217. The fax phone number for the organization where this application or proceeding is assigned is (703) 308-4242.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-0196.

P. Ponnaluri
Patent Examiner
Technology Center 1600
Art Unit 1639
02 October 2002

ADMASHRI PONNALUR PRIMARY EXAMINER